Survival endpoint: Pro

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

Volumn 3, Issue SUPPL. 1, 2002, Pages

  Bensimon, Gilbert ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CILIARY NEUROTROPHIC FACTOR; PLACEBO; RECOMBINANT PROTEIN; RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CHRONIC DISEASE; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG DEVELOPMENT; DRUG EFFICACY; FOLLOW UP; HUMAN; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; SCORING SYSTEM; SIDE EFFECT; STATISTICAL ANALYSIS; SURVIVAL RATE; TACHYPHYLAXIS; VITAL CAPACITY;

EID: 0036393394     PISSN: 14660822     EISSN: None     Source Type: Journal    
DOI: 10.1080/146608202320374237     Document Type: Article

References (5)

1. Rubin DB. Multiple imputation after 18+ years. JASA 1996; 91: 473-489.
2. Miller RG, Petajan JH, Bryan WW et al. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. Ann Neurol 1996; 39: 256-260.
3. ALS CNTF Treatment Study Group. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 1996; 46: 1244-1249.
4. Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976; 34: 585-612.
5. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V and the ALS/Riluzole Study Group. II. Dose ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996; 347: 1425-1431.